Lung Cancer

Upcoming oncology meetings in the second half of 2025 will present new data across tumor types and offering updates that may influence standards of care.

The NCCN guidelines for NSCLC were updated to include zongertinib as a preferred subsequent therapy option for advanced or metastatic HER2-mutant NSCLC.

The FDA has granted breakthrough therapy designation to ifinatamab deruxtecan for the treatment of patients with extensive-stage small cell lung cancer.

Izalontamab brengitecan earned FDA breakthrough therapy designation for EGFR-mutated locally advanced or metastatic NSCLC.

Hematology/oncology fellows shared insights on notable presentations given during the OncLive Fellows Forum on Thoracic Oncology.

Vepdegestrant NDA under FDA review in ESR1-mutated breast cancer, Oncomine Dx Target Test gets greenlit as zongertinib companion diagnostic in NSCLC.

Sonam Puri, MD, discusses advances in small cell lung cancer that have expanded treatment options across disease stages.

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

The FDA granted accelerated approval to zongertinib for pretreated, unresectable or metastatic non–small cell lung cancer harboring HER2 mutations.

Lung cancer experts share upcoming, potentially practice-informing clinical trials that are expected to read out in the second half of 2025.

ASCO updated their clinical practice guidelines for stage IV NSCLC with or without a driver alteration.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss how immunotherapy could continue to reshape early NSCLC management.

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss factors that affect adjuvant treatment decisions in early non–small cell lung cancer.

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Tina Cascone, MD, PhD, discusses of perioperative nivolumab vs placebo in patients with resectable non–small cell lung cancer.

Panelists discuss how the PACIFIC-R real-world data demonstrates excellent long-term outcomes with a median survival of 60 months, validating the durvalumab consolidation approach while addressing management strategies for patients who progress on or after immunotherapy.

Panelists discuss how neoadjuvant chemoimmunotherapy maintains acceptable surgical safety profiles with mortality rates under 4% and how technical complexity primarily stems from hilar lymph node involvement rather than the systemic therapy itself, requiring experienced surgeons to handle these cases.

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Luis E. Raez, MD, FACP, FASCO, dives into evolving practices in molecular testing for patients with lung cancer.

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Perioperative durvalumab sBLA gets priority review in gastric/GEJ cancer, acalabrutinib combination sNDA under review in CLL, and more.

The first-in-class TEAD autopalmitoylation inhibitor VT3989 has received FDA orphan drug designation for the treatment of patients with mesothelioma.

Here is your guide to all therapeutic options that were approved by the FDA in July 2025 spanning tumor types.